| P2093 | author name string | Scott Mittelstadt | |
| | David Rampe | |
| | Alan S Bass | |
| | Gary Gintant | |
| | Karluss Thomas | |
| | Laurie A Hanson | |
| P2860 | cites work | Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence | Q68447410 |
| | Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine | Q71988427 |
| | Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic | Q73764581 |
| | Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit | Q74601471 |
| | Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern | Q80600318 |
| | Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches | Q22337395 |
| | Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability | Q28194506 |
| | Molecular biology of K(+) channels and their role in cardiac arrhythmias | Q31817227 |
| | QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience | Q33942931 |
| | Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children | Q34037717 |
| | An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) | Q34326829 |
| | The significance of QT interval in drug development | Q34808276 |
| | Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development | Q35095735 |
| | Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs | Q35789021 |
| | Mechanism of block and identification of the verapamil binding domain to HERG potassium channels | Q40954779 |
| | Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches | Q42598484 |
| | The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis | Q43596901 |
| | In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol | Q43624950 |
| | Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. | Q43746024 |
| | Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs. | Q43956832 |
| | Rate-correction technique for QT interval in long-term telemetry ECG recording in beagle dogs | Q44229167 |
| | A method for QT correction based on beat-to-beat analysis of the QT/RR interval relationship in conscious telemetred beagle dogs | Q44443079 |
| | Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit | Q46566947 |
| | QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles | Q46717717 |
| | QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals | Q46956297 |
| | Electrocardiographic findings in patients with diphenhydramine overdose. | Q51534405 |
| | Clinical symptomatology of diphenhydramine overdose: an evaluation of 136 cases in 1982 to 1985. | Q51797078 |
| | Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers | Q57005299 |
| | Combined High-performance Liquid Chromatographic Procedure for Measuring 4-hydroxypropranolol and Propranolol in Plasma: Pharmacokinetic Measurements Following Conventional and Slow-Release Propranolol Administration | Q57986975 |
| P433 | issue | 2 | |
| P921 | main subject | circulatory system | Q11068 |
| P304 | page(s) | 116-129 | |
| P577 | publication date | 2006-05-09 | |
| P1433 | published in | Journal of Pharmacological and Toxicological Methods | Q15724529 |
| P1476 | title | ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. | |
| P478 | volume | 54 | |